Clinical Trials

ISM Sensors for M800 and M300 Transmitters

METTLER TOLEDO Thornton M800 and M300 ISM process analytical instrumentation provides reliable, accurate measurements of conductivity/resistivity, pH/ORP, dissolved oxygen and dissolved ozone. On-board digital measurement and Intelligent Sensor Management (ISM) technology provide the utmost in convenience and control of sensor performance.

PhaseBio gets FDA nod to begin Covid-19 trial with VIP receptor agonist PB1046

PhaseBio Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) to begin a VANGARD pivotal clinical to assess PB1046 as a treatment for hospitalised Covid-19 patients.

Algernon submits IND application with FDA for possible Covid-19 treatment

Algernon Pharmaceuticals has completed the submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to assess the Ifenprodil in the phase 2b/3 clinical study to treat Covid-19 patients.

Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints

Antisense Therapeutics is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.

Appili set to evaluate favipiravir as preventive measure against Covid-19

Appili Therapeutics has secured regulatory clearance from Health Canada to move ahead with a phase 2 study for studying FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against the outbreak of novel coronavirus (Covid-19).

Gilead and Galapagos announce positive topline results of phase 2b/3 trial of filgotinib in moderately to severely active ulcerative colitis

Gilead Sciences and Galapagos announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC).

FDA approves Octapharma USA’s IND application to begin trial with severe Covid-19 patients

Octapharma USA has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to begin a phase three clinical trial to assess the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in Covid-19 patients with severe disease progression.

Janssen announces phase 1 results for amivantamab in advanced NSCLC harbouring Exon 20 insertion mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.

Moderna’s Covid-19 vaccine shows significant effect in early human trial

Moderna announced that its mRNA-1273 vaccine candidate against novel coronavirus (SARS-CoV-2) has demonstrated a significant effect in an early human trial.